drugset
drugset / Trial / NCT04948203

Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis

NCT04948203 ↗

Phase 2/3 Active not recruiting 60 enrolled University of Chicago
RandomizedParallel-groupOpen-labelPrevention

Summary

The primary purpose of this study is to determine whether the drug sirolimus reduces the likelihood of developing of pulmonary fibrosis in patients who are hospitalized with COVID-19 pneumonia.

Timeline

Start
2021-07-09
Primary completion
2026-12
Completion
2026-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Sirolimus Small molecule 0.5 mg Oral
Comparator Sirolimus Small molecule 1 mg Oral
Comparator Sirolimus Small molecule 2 mg Oral

Indications

long COVID-19 pneumonia pulmonary fibrosis